Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Joint Authors
Wang, Xian
Zhang, Fuchun
Zhang, Zhe
Wang, Guang
Yu, Jie
Wei, Jinru
Mao, Jieming
He, Liyun
Source
Issue
Vol. 2008, Issue 2008 (31 Dec. 2008), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2008-12-18
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Natural & Life Sciences (Multidisciplinary)
Biology
Abstract EN
Background.
We investigated the level of soluble adhesion molecules in diabetic patients and the effect of the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone on plasma levels of adhesion molecules and an inflammation marker in type 2 diabetic patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI).
Methods.
A total of 116 diabetic patients with CAD who had undergone PCI were randomized to receive rosiglitazone (4 mg/d) or not for 6 months.
Plasma levels of soluble intercellular adhesion molecules (sICAM-1) and P-selectin (sP-selectin) were measured on ELISA.
Results.
After 6-month rosiglitazone treatment, plasma levels of sICAM-1 were lower than baseline and control group levels (370.4 (332.4–421.9) pg/mL versus 423.5 (327.4–500.3) pg/mL and 404.6 (345.2–483.4) pg/mL, P<.001).
In addition, plasma levels of C-reactive protein were significantly reduced from baseline levels.
However, plasma level of sP-selectin was not significantly lowered with rosiglitazone treatment than with control treatment after 6-month follow-up.
Conclusions.
Rosiglitazone reduces chronic inflammatory responses and improves levels of markers of endothelial dysfunction in patients with diabetes and CAD.
PPAR-γ agonist may have a beneficial effect on the vascular endothelium through its anti-inflammatory mechanism and may be useful as therapy in patients undergoing PCI.
American Psychological Association (APA)
Wang, Guang& Zhang, Zhe& Yu, Jie& Zhang, Fuchun& He, Liyun& Wei, Jinru…[et al.]. 2008. Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease. PPAR Research،Vol. 2008, no. 2008, pp.1-7.
https://search.emarefa.net/detail/BIM-480528
Modern Language Association (MLA)
Wang, Guang…[et al.]. Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease. PPAR Research No. 2008 (2008), pp.1-7.
https://search.emarefa.net/detail/BIM-480528
American Medical Association (AMA)
Wang, Guang& Zhang, Zhe& Yu, Jie& Zhang, Fuchun& He, Liyun& Wei, Jinru…[et al.]. Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease. PPAR Research. 2008. Vol. 2008, no. 2008, pp.1-7.
https://search.emarefa.net/detail/BIM-480528
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-480528